SFDA Approves Pyrukynd As First Treatment For Adult Thalassemia Patients

The Saudi Food and Drug Authority (SFDA) has given the green light for Pyrukynd (Mitapivat) to treat adults with alpha- or beta-thalassemia. This approval marks a regulatory milestone for this specific medical use. Pyrukynd was previously recognised as a "Breakthrough Medicine" by the SFDA, aimed at speeding up access to innovative treatments.

Thalassemia is a genetic blood disorder that affects hemoglobin production, leading to low levels of hemoglobin and fewer healthy red blood cells. Symptoms often include fatigue, weakness, shortness of breath, and heart rhythm issues. Mitapivat is an oral treatment that activates the pyruvate kinase enzyme in red blood cells, enhancing their production and lifespan while reducing transfusion needs.

Clinical trials have shown promising results for Pyrukynd. Two global Phase 3 studies demonstrated its effectiveness in patients with Thalassemia alpha and beta. The first study focused on non-transfusion-dependent patients, showing a significant rise in hemoglobin levels. The second study involved transfusion-dependent patients, revealing a notable decrease in transfusion requirements.

The SFDA's decision to register Pyrukynd was based on comprehensive evidence of its efficacy, safety, and quality. The drug met all necessary standards during evaluation. The positive outcomes from these trials supported a favourable benefit-risk assessment for its approved use.

The SFDA’s Breakthrough Medicines Program aims to expedite access to innovative treatments that show promising efficacy and safety in serious diseases. This initiative aligns with the Health Sector Transformation Program under Vision 2030. It seeks to broaden therapy options and provide early access to breakthrough medicines.

To qualify as a "Breakthrough Medicine," a drug must target serious conditions, offer significant therapeutic benefits over existing treatments, and not be registered with other regulatory bodies at application time. The program supports faster availability of such medicines.

Side Effects and Monitoring

Common side effects noted during clinical studies of Pyrukynd included insomnia and headaches. The SFDA stressed the importance of liver enzyme tests before starting treatment and monthly monitoring during the initial six months.

This approval signifies progress in treating thalassemia, offering hope for improved patient outcomes through reduced transfusion dependency and enhanced quality of life.

With inputs from SPA